Laboratories

print

Laboratories

Update : 2019-08-28

Overview

 To provide better, safer, and personalized therapy to cancer patients, we are developing novel diagnostic technologies and therapeutic strategies. Cancer cells possess individual heterogeneous properties, such as genomic mutation patterns, progression speed, or drug responses. Therefore to realize “the cancer precision medicine”, development of precise biomarkers is essential, which can define these clinical features based on molecular biology.

  Our team “Project for Realization of Personalized Cancer Medicine” analyzes a large number of cancer tissue of blood samples using leading-edge mass spectrometry technologies to acquire a whole view of protein frameworks and networks in cancer cells or body fluids. By integrating them with genomic dataset, we aim to identify key factors (biomarkers) defining biological characteristics and clinical outcomes of cancer.

Projects

  • Identification of cancer-specific glycan biomarkers by glycoproteomics
  • Development of cancer liquid biopsy diagnostics based on extracellular vesicles (exosomes)
  • Establishment of innovative cancer immuno-therapy using proteogenomics

Publications

  1. Identification of Multisialylated LacdiNAc Structures as Highly Prostate Cancer Specific Glycan Signatures on PSA
    Haga, Y., Uemura, M., Baba, S., Inamura, K., Takeuchi, K., Nonomura, N., and Ueda, K.
    Analytical chemistry, (2019) 91, 2247.
  2. Citrullination of RGG Motifs in FET Proteins by PAD4 Regulates Protein Aggregation and ALS Susceptibility
    Tanikawa, C., Ueda, K., Suzuki, A., Iida, A., Nakamura, R., Atsuta, N., Tohnai, G., Sobue, G., Saichi, N., Momozawa, Y., Kamatani, Y., Kubo, M., Yamamoto, K., Nakamura, Y., and Matsuda, K.
    Cell Rep, (2018) 22, 1473-1483.
  3. Extracellular vesicles isolated from human renal cell carcinoma tissues disrupt vascular endothelial cell morphology via azurocidin
    Jingushi, K., Uemura, M., Ohnishi, N., Nakata, W., Fujita, K., Naito, T., Fujii, R., Saichi, N., Nonomura, N., Tsujikawa, K., and Ueda, K.
    Int J Cancer, (2018) 142, 607-617.
  4. Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53
    Miyamoto, T., Lo, P.H.Y., Saichi, N., Ueda, K., Hirata, M., Tanikawa, C., and Matsuda, K.
    Sci Adv, (2017) 3, e1603204.
  5. A plasma diagnostic model of human T-cell leukemia virus-1 associated myelopathy
    Ishihara, M., Araya, N., Sato, T., Saichi, N., Fujii, R., Yamano, Y., and Ueda, K.
    Ann Clin Transl Neurol, (2015) 2, 231-240.
  6. Preapoptotic protease calpain-2 is frequently suppressed in adult T-cell leukemia
    Ishihara, M., Araya, N., Sato, T., Tatsuguchi, A., Saichi, N., Utsunomiya, A., Nakamura, Y., Nakagawa, H., Yamano, Y., and Ueda, K.
    Blood, (2013) 121, 4340-4347.

Contact

Koji Ueda (Project Leader)
Project for Realization of Personalized Cancer Medicine,
Cancer Precision Medicine Center, Japanese Foundation for Cancer Research 
3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan
Tel: +81-3-3570-0658 Fax: +81-3-3570-0644 E-mail: koji.ueda@jfcr.or.jp

Return to Top of Page